<p>药明康德（NASDAQ:BEAM - 获取免费报告）在周五发布给客户和投资者的研究报告中，被美国银行从 “中性” 评级上调至 “买入” 评级，Briefing.com 自动导入报告称。该券商目前对该股票的目标价为 42.00 美元。美国银行的目标价表明，与公司当前价格相比，潜在上涨幅度为 89.27%。</p>
<p>获取 <strong>Beam Therapeutics</strong> 警报：</p>
<ul>
<li>MarketBeat 周回顾 – 3/4 – 3/8</li>
</ul>
<p>其他一些股票研究分析师也对该股票发表了看法。加拿大皇家银行将药明康德的目标价从 24.00 美元上调至 26.00 美元，并在 2 月 26 日的研究报告中给予该公司 “行业表现” 评级。古根海姆在 2 月 27 日的报告中重申了 “买入” 评级，并对药明康德的股票发布了 78.00 美元的目标价。Wedbush 在 3 月 10 日的报告中重申了 “跑赢大盘” 评级，并设定了 57.00 美元的目标价。加拿大丰业银行在 3 月 10 日的报告中将药明康德的评级从 “行业表现” 上调至 “行业跑赢大盘”，并设定了 40.00 美元的目标价。最后，Cantor Fitzgerald 在 3 月 12 日的研究报告中重申了对药明康德股票的 “增持” 评级。两位分析师对该股票给予了持有评级，十位分析师给予了买入评级，另外两位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，共识目标价为 49.45 美元。</p>
<p><strong>获取我们最新的 BEAM 股票分析</strong></p>
<h2>Beam Therapeutics 股票上涨 1.3%</h2>
<ul>
<li>Beam Therapeutics 因基因治疗许可付款而大幅上涨</li>
</ul>
<p>NASDAQ:BEAM 周五开盘价为 22.19 美元。该股票的市值为 22.1 亿美元，市盈率为-12.61，贝塔值为 1.91。该公司的 50 日移动平均线为 26.67 美元，200 日移动平均线为 25.87 美元。药明康德的 12 个月低点为 20.84 美元，12 个月高点为 35.25 美元。</p>
<p>药明康德（NASDAQ:BEAM - 获取免费报告）最近一次发布财报是在 2 月 25 日。该公司报告本季度每股收益为（1.09 美元），超出市场共识预期的（1.25 美元）0.16 美元。该季度的营业收入为 3000 万美元，而市场共识预期为 1647 万美元。药明康德的股本回报率为-16.22%，净利润率为-41.07%。该公司的收入与去年同期相比下降了 90.5%。去年同期，该公司每股收益为 1.73 美元。研究分析师预测，药明康德在本年度的每股收益将为-4.57 美元。</p>
<h2>Beam Therapeutics 内部活动</h2>
<ul>
<li>CRISPR Therapeutics 是基因编辑领域的 NVIDIA 吗？</li>
</ul>
<p>在其他新闻中，首席执行官 John M. Evans 于 1 月 30 日出售了 30,000 股药明康德股票，交易价格为 26.75 美元，总价值为 802,500.00 美元。出售后，首席执行官现在持有 908,659 股公司股票，价值为 24,306,628.25 美元。此次交易使其持股比例减少了 3.20%。该交易在向证券交易委员会的法律文件中披露，相关文件可通过此链接访问。此外，内部人士 Christine Bellon 于 1 月 2 日出售了 1,241 股药明康德股票，交易价格为 24.68 美元，总价值为 30,627.88 美元。出售完成后，该内部人士现在持有 102,968 股公司股票，价值约为 2,541,250.24 美元。此次交易使其持股比例减少了 1.19%。该交易的披露信息可以在此找到。内部人士持有公司股票的 4.20%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近增加或减少了对公司的持股。Wealthfront Advisers LLC 在第四季度购买了价值 41,000 美元的药明康德新股份。GF Fund Management CO. LTD. 在第四季度购买了价值 43,000 美元的药明康德新股份。Sterling Capital Management LLC 在第四季度将其在药明康德的持股增加了 816.0%。Sterling Capital Management LLC 现在持有 2,409 股公司股票，价值 60,000 美元，此前在该期间内又购买了 2,146 股。KBC Group NV 在第四季度将其在药明康德的持股增加了 103.2%。KBC Group NV 现在持有 4,143 股公司股票，价值 103,000 美元，此前在上个季度又购买了 2,104 股。最后，Blue Trust Inc. 在第四季度将其在药明康德的持股增加了 36.3%。Blue Trust Inc. 现在持有 4,274 股公司股票，价值 105,000 美元，此前在该期间内又购买了 1,139 股。机构投资者和对冲基金持有公司 99.68% 的股票。</p>
<h2>Beam Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>药明康德是一家生物技术公司，专注于为美国患有严重疾病的患者开发精准基因药物。它开发了用于治疗镰状细胞病或β-地中海贫血的 BEAM-101；用于治疗严重的α-1 抗胰蛋白酶缺乏症的肝脏靶向 LNP 制剂 BEAM-302；用于治疗难治性 T 细胞急性淋巴细胞白血病/T 细胞淋巴母细胞瘤的抗 CD7 CAR-T 产品候选药物 BEAM-201，目前处于 1/2 期临床试验阶段；以及用于治疗糖原贮积病 1a 的肝脏靶向 LNP 制剂 BEAM-301。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Beam Therapeutics</li>
<li>优先股与普通股的投资</li>
<li>3 只接近 52 周高点的动量股，值得关注以获取更多增长</li>
<li>商业服务股票投资</li>
<li>微软在马来西亚的大赌注可能会为投资者带来回报</li>
<li>一些最佳的大盘股有哪些？</li>
<li>市场上被严重超卖的五只股票是…</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Beam Therapeutics 吗？</h2>
<p>在考虑 Beam Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Beam Therapeutics 并不在名单上。</p>
<p>虽然 Beam Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BEAM

<p>美国银行将 Beam Therapeutics（纳斯达克代码：BEAM）的评级从 “中性” 上调至 “买入”，设定目标价格为 42.00 美元，暗示潜在上涨空间为 89.27%。其他分析师也提高了他们的目标价格，普遍评级为 “买入”，平均目标为 49.45 美元。Beam Therapeutics 报告的季度每股收益为（1.09 美元），超出预期，收入为 3000 万美元。该股开盘价为 22.19 美元，市值为 22.1 亿美元。内部交易活动包括首席执行官 John M. Evans 出售了 30,000 股</p>

<p>Beam Therapeutics (NASDAQ:BEAM - Get Free Report) was upgraded by Bank of America from a &#34;neutral&#34; rating to a &#34;buy&#34; rating in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The brokerage presently has a $42.00 price objective on the stock. Bank of America's price target indicates a potential upside of 89.27% from the company's current price.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:BEAM - 获取免费报告）在周五发布给客户和投资者的研究报告中，被美国银行从 “中性” 评级上调至 “买入” 评级，Briefing.com 自动导入报告称。该券商目前对该股票的目标价为 42.00 美元。美国银行的目标价表明，与公司当前价格相比，潜在上涨幅度为 89.27%。</p>
</div><p>Get <strong>Beam Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Beam Therapeutics</strong> 警报：</p>
</div><ul>
<li>MarketBeat Week in Review – 3/4 – 3/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 3/4 – 3/8</li>
</ul>
</div><p>A number of other equities research analysts have also weighed in on the stock. Royal Bank of Canada lifted their target price on shares of Beam Therapeutics from $24.00 to $26.00 and gave the company a &#34;sector perform&#34; rating in a research note on Wednesday, February 26th. Guggenheim restated a &#34;buy&#34; rating and issued a $78.00 price objective on shares of Beam Therapeutics in a report on Thursday, February 27th. Wedbush reaffirmed an &#34;outperform&#34; rating and set a $57.00 price target on shares of Beam Therapeutics in a report on Monday, March 10th. Scotiabank raised Beam Therapeutics from a &#34;sector perform&#34; rating to a &#34;sector outperform&#34; rating and set a $40.00 target price on the stock in a report on Monday, March 10th. Finally, Cantor Fitzgerald restated an &#34;overweight&#34; rating on shares of Beam Therapeutics in a research note on Wednesday, March 12th. Two analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Buy&#34; and a consensus target price of $49.45.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也对该股票发表了看法。加拿大皇家银行将药明康德的目标价从 24.00 美元上调至 26.00 美元，并在 2 月 26 日的研究报告中给予该公司 “行业表现” 评级。古根海姆在 2 月 27 日的报告中重申了 “买入” 评级，并对药明康德的股票发布了 78.00 美元的目标价。Wedbush 在 3 月 10 日的报告中重申了 “跑赢大盘” 评级，并设定了 57.00 美元的目标价。加拿大丰业银行在 3 月 10 日的报告中将药明康德的评级从 “行业表现” 上调至 “行业跑赢大盘”，并设定了 40.00 美元的目标价。最后，Cantor Fitzgerald 在 3 月 12 日的研究报告中重申了对药明康德股票的 “增持” 评级。两位分析师对该股票给予了持有评级，十位分析师给予了买入评级，另外两位分析师给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “买入”，共识目标价为 49.45 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on BEAM</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 BEAM 股票分析</strong></p>
</div><h2>Beam Therapeutics Trading Up 1.3 %</h2>
<div class="lb-trans"><h2>Beam Therapeutics 股票上涨 1.3%</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可付款而大幅上涨</li>
</ul>
</div><p>NASDAQ:BEAM opened at $22.19 on Friday. The stock has a market capitalization of $2.21 billion, a PE ratio of -12.61 and a beta of 1.91. The firm's 50 day moving average is $26.67 and its 200 day moving average is $25.87. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $35.25.</p>
<div class="lb-trans"><p>NASDAQ:BEAM 周五开盘价为 22.19 美元。该股票的市值为 22.1 亿美元，市盈率为-12.61，贝塔值为 1.91。该公司的 50 日移动平均线为 26.67 美元，200 日移动平均线为 25.87 美元。药明康德的 12 个月低点为 20.84 美元，12 个月高点为 35.25 美元。</p>
</div><p>Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.16. The business had revenue of $30.00 million during the quarter, compared to the consensus estimate of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The firm's revenue was down 90.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.73 EPS. Research analysts predict that Beam Therapeutics will post -4.57 earnings per share for the current year.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:BEAM - 获取免费报告）最近一次发布财报是在 2 月 25 日。该公司报告本季度每股收益为（1.09 美元），超出市场共识预期的（1.25 美元）0.16 美元。该季度的营业收入为 3000 万美元，而市场共识预期为 1647 万美元。药明康德的股本回报率为-16.22%，净利润率为-41.07%。该公司的收入与去年同期相比下降了 90.5%。去年同期，该公司每股收益为 1.73 美元。研究分析师预测，药明康德在本年度的每股收益将为-4.57 美元。</p>
</div><h2>Insider Activity at Beam Therapeutics</h2>
<div class="lb-trans"><h2>Beam Therapeutics 内部活动</h2>
</div><ul>
<li>Is CRISPR Therapeutics the NVIDIA of gene editing?</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 是基因编辑领域的 NVIDIA 吗？</li>
</ul>
</div><p>In other news, CEO John M. Evans sold 30,000 shares of Beam Therapeutics stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $26.75, for a total value of $802,500.00. Following the sale, the chief executive officer now owns 908,659 shares of the company's stock, valued at $24,306,628.25. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now owns 102,968 shares in the company, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 John M. Evans 于 1 月 30 日出售了 30,000 股药明康德股票，交易价格为 26.75 美元，总价值为 802,500.00 美元。出售后，首席执行官现在持有 908,659 股公司股票，价值为 24,306,628.25 美元。此次交易使其持股比例减少了 3.20%。该交易在向证券交易委员会的法律文件中披露，相关文件可通过此链接访问。此外，内部人士 Christine Bellon 于 1 月 2 日出售了 1,241 股药明康德股票，交易价格为 24.68 美元，总价值为 30,627.88 美元。出售完成后，该内部人士现在持有 102,968 股公司股票，价值约为 2,541,250.24 美元。此次交易使其持股比例减少了 1.19%。该交易的披露信息可以在此找到。内部人士持有公司股票的 4.20%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the company. Wealthfront Advisers LLC purchased a new stake in shares of Beam Therapeutics during the 4th quarter valued at $41,000. GF Fund Management CO. LTD. purchased a new position in shares of Beam Therapeutics in the 4th quarter valued at $43,000. Sterling Capital Management LLC raised its stake in shares of Beam Therapeutics by 816.0% in the 4th quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock valued at $60,000 after acquiring an additional 2,146 shares during the period. KBC Group NV lifted its holdings in shares of Beam Therapeutics by 103.2% during the 4th quarter. KBC Group NV now owns 4,143 shares of the company's stock valued at $103,000 after acquiring an additional 2,104 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in Beam Therapeutics by 36.3% during the 4th quarter. Blue Trust Inc. now owns 4,274 shares of the company's stock worth $105,000 after purchasing an additional 1,139 shares during the period. Institutional investors and hedge funds own 99.68% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对公司的持股。Wealthfront Advisers LLC 在第四季度购买了价值 41,000 美元的药明康德新股份。GF Fund Management CO. LTD. 在第四季度购买了价值 43,000 美元的药明康德新股份。Sterling Capital Management LLC 在第四季度将其在药明康德的持股增加了 816.0%。Sterling Capital Management LLC 现在持有 2,409 股公司股票，价值 60,000 美元，此前在该期间内又购买了 2,146 股。KBC Group NV 在第四季度将其在药明康德的持股增加了 103.2%。KBC Group NV 现在持有 4,143 股公司股票，价值 103,000 美元，此前在上个季度又购买了 2,104 股。最后，Blue Trust Inc. 在第四季度将其在药明康德的持股增加了 36.3%。Blue Trust Inc. 现在持有 4,274 股公司股票，价值 105,000 美元，此前在该期间内又购买了 1,139 股。机构投资者和对冲基金持有公司 99.68% 的股票。</p>
</div><h2>Beam Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Beam Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.</p>
<div class="lb-trans"><p>药明康德是一家生物技术公司，专注于为美国患有严重疾病的患者开发精准基因药物。它开发了用于治疗镰状细胞病或β-地中海贫血的 BEAM-101；用于治疗严重的α-1 抗胰蛋白酶缺乏症的肝脏靶向 LNP 制剂 BEAM-302；用于治疗难治性 T 细胞急性淋巴细胞白血病/T 细胞淋巴母细胞瘤的抗 CD7 CAR-T 产品候选药物 BEAM-201，目前处于 1/2 期临床试验阶段；以及用于治疗糖原贮积病 1a 的肝脏靶向 LNP 制剂 BEAM-301。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Beam Therapeutics</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>3 Momentum Stocks Near 52-Week Highs to Watch for More Growth</li>
<li>Business Services Stocks Investing</li>
<li>Microsoft’s Big Malaysia Bet Could Pay Off for Investors</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>The 5 Most Oversold Stocks on the Market Are…</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Beam Therapeutics</li>
<li>优先股与普通股的投资</li>
<li>3 只接近 52 周高点的动量股，值得关注以获取更多增长</li>
<li>商业服务股票投资</li>
<li>微软在马来西亚的大赌注可能会为投资者带来回报</li>
<li>一些最佳的大盘股有哪些？</li>
<li>市场上被严重超卖的五只股票是…</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BEAM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Beam Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Beam Therapeutics 吗？</h2>
</div><p>Before you consider Beam Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Beam Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Beam Therapeutics 并不在名单上。</p>
</div><p>While Beam Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Beam Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Beam Therapeutics（纳斯达克股票代码：BEAM）在美国银行被上调至买入评级